Canada markets closed

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9348+0.0334 (+3.71%)
At close: 04:00PM EDT
0.9100 -0.02 (-2.65%)
After hours: 04:38PM EDT

Acasti Pharma Inc.

3009 boulevard de la Concorde East
Suite 102
Laval, QC H7E 2B5
Canada

https://www.acastipharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Janelle D'AlvisePres, CEO, Corp. Sec. & Director428.04kN/A1956
Dr. Pierre Lemieux M.D., Ph.D.Co-Founder, COO & Chief Scientific Officer276.38kN/A1965
Mr. Brian D. Ford CPA, CAChief Financial Officer364.82kN/A1959
Dr. Yves Lachance Ph.D.VP of Quality & ComplianceN/AN/AN/A
Dr. George KottayilChief Operating Officer of USN/AN/AN/A
Mr. Prashant KohliVP of Commercial OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Corporate Governance

Acasti Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.